OCT 22, 2021 12:35 PM PDT

Cannabinoid Pain Treatment for Kidney Disease Patients

WRITTEN BY: Kerry Charron

According to a recent review of cannabis in kidney disease symptom management conducted by University of British Columbia researchers, cannabis treatment has the potential to manage symptoms of chronic kidney disease (CKD) and end stage renal disease (ESRD). The review highlighted the effectiveness of cannabis’s effectiveness in managing neuropathic pain that afflicts a majority of patients undergoing renal replacement therapy such as dialysis. The researchers found that using the lowest cannabis dosage possible was effective for pain management and offered a less addictive alternative to opioid pain management options.

Cannabinoid research has been hindered by historical stigma and illegal status, so there is minimal established research on cannabis’s adverse effects and benefits for patients with CKD. Mount Sinai Hospital Nephrologist Dr. Joshua Rein pointed out the importance of knowing the side effect profile of each route of administration in light of mixed evidence highlighting the benefits and potential adverse effects of cannabis. Some studies suggest that there may be an increased risk of heart attacks or stroke for some patients, while some studies may show an increased risk of lung infection. Overall, Dr. Rein recommends that CKD patients with pulmonary and respiratory diseases avoid smoking and instead seek out other options such as topical creams, tinctures, and edibles.

As cannabis treatments for those with CKD become more prevalent, this increased access will potentially reduce opioid dependence. Over 60% of dialysis patients have at least one opioid prescription despite mixed results regarding opioid’s effectiveness in pain reduction. Cannabis is reported to alleviate the pain, nausea and anxiety afflicting CKD patients.

Research on cannabinoids and renal function will continue to explore the roles that CB1 and CB2 receptors play in cannabinoid kidney treatments. Both receptors may be possible therapeutic targets managing renal deterioration due to diabetes. Future research will also explore the properties of different cannabinoids and most appropriate strains for CKD patients.

 

Sources: Canadian Journal of Kidney Health & Disease, Current Opinion in Nephrology and Hypertension

About the Author
  • Kerry Charron writes about medical cannabis research. She has experience working in a Florida cultivation center and has participated in advocacy efforts for medical cannabis.
You May Also Like
JUN 16, 2021
Health & Medicine
CBD Consumption Linked With Lower Alcohol Intake
JUN 16, 2021
CBD Consumption Linked With Lower Alcohol Intake
Drink and drugs and rock ‘n’ roll may have defined the life of a few in the seventies, but the  fact of ...
JUN 24, 2021
Health & Medicine
Cannabis Use in Military Vets on the Increase
JUN 24, 2021
Cannabis Use in Military Vets on the Increase
A new study shows an increase in the number of U.S. military veterans using cannabis, although Veteran Affairs doctors s ...
AUG 04, 2021
Health & Medicine
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
AUG 04, 2021
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
  A phase II trial is being planned to test the cannabis-derived drug Sativex, in patients with aggressive brain tu ...
AUG 18, 2021
Cannabis Sciences
Cannabis Use Disorder Linked to COVID Hospitalization
AUG 18, 2021
Cannabis Use Disorder Linked to COVID Hospitalization
People with a genetic predisposition to cannabis use disorder (CUD) are more likely to require hospitalization after con ...
AUG 21, 2021
Health & Medicine
Teenage Cannabis Link to Poorer Birth Outcomes Two Decades Later
AUG 21, 2021
Teenage Cannabis Link to Poorer Birth Outcomes Two Decades Later
A new study suggests that females and males who were frequent users of cannabis while teenagers are more likely to becam ...
NOV 16, 2021
Health & Medicine
Psilocybin and Cannabis to Treat Anxiety and Addiction
NOV 16, 2021
Psilocybin and Cannabis to Treat Anxiety and Addiction
Johns Hopkins University Center for Psychedelic and Consciousness Research just received a $4.9 million grant to study h ...
Loading Comments...